Xspray Pharma
24.65 SEK
-1.40 %
Less than 1K followers
XSPRAY
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-1.40 %
-2.18 %
-21.62 %
-20.48 %
-48.21 %
-12.86 %
-66.93 %
-77.52 %
-18.38 %
Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.
Read moreMarket cap
1.03B SEK
Turnover
653.73K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
6/5
2026
Interim report Q1'26
12/5
2026
General meeting '26
5/8
2026
Interim report Q2'26
All
Webcasts
Press releases
ShowingAll content types
Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc® – PDUFA date August 25, 2026
Xspray Pharma lämnar in uppdaterad FDA-ansökan för Dasynoc
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
